Primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma is rare, and the optimal frontline treatment has not taken shape so far. It is still debatable whether the watch-and-wait (W&W) policy is beneficial to patients, especially in the early stage. This study was to compare the efficacy of W&W with rituximab single agent or combined chemotherapy (R/R-Chemo) on primary pulmonary MALT patients with localized disease. Clinical characters and effect on 28 patients with primary pulmonary MALT (IE phase) were analyzed. Among the 28 patients, 14 were grouped into W&W cohort, and 14 were immediately treated with R/R-Chemo. The median follow-up duration was 62 months. The estimated median time to treatment failure (TTF) in the W&W cohort and immediate R/R-Chemo cohort was 29 months and 59 months, which were not significantly different (P = 0.667). The estimated median time of overall survival (OS) in the W&W cohort and immediate R/R-Chemo cohort was 78 months and 76 months, which were also not statistically significant (P = 0.696). Concerning prognosis, there is no difference between patients with primary pulmonary MALT (IE phase) treated with W&W and with timely R/R-Chemo.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
The data was identified by searching clinical databases from three institutions (Shengjing Hospital of China Medical University, The First Affiliated Hospital of China Medical University, and Cancer Hospital of China Medical University).
Kobayashi Y (2019) JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-2. Marginal zone lymphoma (MALT lymphoma/extranidal marginal zone lymphoma of mucosa-associated lymphoid tissue and splenic marginal zone lymphoma). Int J Hematol 110:393–405. https://doi.org/10.1007/s12185-019-02719-6
Couto C, Martins V, Ribeiro V, Rodrigues C, Nogueira J, Oliveira A, Vieira JR (2019) Primary pulmonary MALT lymphoma: a case report and literature review. Biomed Hub 4:1–5. https://doi.org/10.1159/000502488
Borie R, Wislez M, Antoine M et al (2016) Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. Eur Respir J 48:1252–1255. https://doi.org/10.1159/000502488
Sammassimo S, Pruneri G, Andreola G, Montoro J, Steffanoni S, Nowakowski GS, Gandini S, Negri M, Habermann TM, Raderer M, Li ZM, Zinzani PL, Adam P, Zucca E, Martinelli G (2016) A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of international extranodal lymphoma study group (IELSG). Hematol Oncol 34:177–183. https://doi.org/10.1002/hon.2243
Oh SY, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Lee GW, Choi CW, Park J, Suh C, Kim HJ (2010) Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: consortium for improving survival of lymphoma (CISL) study. Ann Hematol 89:563–568. https://doi.org/10.1007/s00277-009-0875-7
Wise LM, Arkfeld DG (2020) A patient with primary sjogren’s syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review. Clin Rheumatol 39:1357–1362. https://doi.org/10.1007/s10067-019-04886-7
Alvarez-Sánchez AI, MartÍnez-Losada C (2018) Rituximab monotherapy become an optimal treatment for primary pulmonary malt lymphoma. Leuk Res Rep 9:21–22. https://doi.org/10.1016/j.lrr.2018.02.004
Swerdlow SH, Campo E, Harris NL et al (2008) Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). 4th ed. Lyon: International Agency for Research on Cancer (IARC)
Graham BB, Mathisen DJ, Mark EJ et al (2005) Primary pulmonary lymphoma. Ann Thorac Surg 80:1248–1253. https://doi.org/10.1016/j.athoracsur.2005.04.014
Huang HH, Ko BS, Chen HM, Chen LJ, Wang CY, Hsiao FY (2020) Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: a population-based study in Taiwan, 2010-2015. Immun Ageing 17:17. https://doi.org/10.1186/s12979-020-00188-8
Kelemen K, Rimsza LM, Craig FE (2020) Primary pulmonary B-cell lymphoma. Semin Diagn Pathol S0740-2570:30036–30038. https://doi.org/10.1053/j.semdp.2020.04.002
Wang Y, Han J, Zhang F, Wang Z, Zhao D, Wang X, Wu N, Lu R, Wu C, Gao J, Pan L, Xue X (2019) Comparison of radiologic characteristics and pathological presentations of primary pulmonary lymphoma in 22 patients. J Int Med Res 27:300060519879854. https://doi.org/10.1177/0300060519879854
Wang L, Ye G, Liu Z, Shi L, Zhan C, Gu J, Luo R, Lin Z, Ge D, Wang Q (2019) Clinical characteristics, diagnosis, treatment, and prognostic factors of pulmonary mucosa-associated lymphoid tissue-derived lymphoma. Cancer Med 8:7660–7668. https://doi.org/10.1002/cam4.2683
Wang B, Zhang C, Wang B, Zhang L (2015) Comparisons of surgery and/or chemotherapy in the treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma. Ann Thorac Cardiovasc Surg 21:109–113. https://doi.org/10.5761/atcs.oa.14-00145
Girinsky T, Paumier A, Ferme C, Hanna C, Ribrag V, Leroy-Ladurie F, Ghalibafian M (2012) Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients. Int J Radiat Oncol Biol Phys 83:e385–e389. https://doi.org/10.1016/j.ijrobp.2012.01.005
Okamura I, Imai H, Mori K, Ogura K, Isoda A, Mihara K, Matsumoto M, Saito R, Takahashi T, Ikeda T (2015) Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma. Int J Hematol 101:46–51. https://doi.org/10.1007/s12185-014-1694-8
Ogusa E, Tomita N, Ishii Y, Takasaki H, Hattori Y, Matsumoto C, Ishigatsubo Y (2013) Clinical manifestations of primary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population. Hematol Oncol 31:18–21. https://doi.org/10.1002/hon.2008
Du C, Zhang JQ, Wei Y et al (2018) Retrospective analysis of 9 cases of primary pulmonary mucosa-associated lymphoid tissue lymphoma and literature review. Med Sci Monit Basic Res 24:233–240. https://doi.org/10.12659/MSMBR.912762
Seker M, Bilici A, Ustaalioglu BO, Salman T, Sonmez B, Canpolat NA, Salepci T, Gumus M, Yaylaci M (2009) Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma. Leuk Res 33:e154–e156. https://doi.org/10.1016/j.leukres.2009.03.026
Jhaveri K, Dimas DJ, Vakil A, Surani S (2019) Primary pulmonary involvement in mucosa-associated lymphoid tissue lymphoma. Cureus 11:e5110. https://doi.org/10.7759/cureus.5110
Defrancesco I, Arcaini L (2018) Overview on the management of non-gastric MALT lymphomas. Best Pract Res Clin Haematol 31:57–64. https://doi.org/10.1016/j.beha.2017.11.001
Torch M, Streubel B, Petkov V et al (2007) Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res 27:3633–3637. https://doi.org/10.1016/j.leukres.2009.03.026
Zhang MC, Zhou M, Song Q, Wang S, Shi Q, Wang L, Yan FH, Qu JM, Zhao WL (2019) Clinical features and outcomes of pulmonary lymphoma: a single center experience of 180 cases. Lung Cancer 132:39–44. https://doi.org/10.1016/j.lungcan.2019.04.004
Lévy M, Copie-Bergman C, Amiot A, Dupuis J, Baleur YL, Belhadj K, Hémery F, Sobhani I, Delfau-Larue MH, Leroy K, Haioun C, Delchier JC (2013) Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma 54:940–944. https://doi.org/10.3109/10428194.2012.729832
We would like to express our greatest gratitude to all the physicians and institutions involved in this study for their support. We would like to thank the pathology, thoracic surgery, and hematology departments of three institutions for providing us with the patient data. Thanks to the Natural Science Foundation of Liaoning Province for its support.
This study was funded by the Natural Science Foundation of Liaoning Province (201800875, 2018; 20180551257, 2018).
Conflict of interest
The authors declare that they have no conflict of interest.
This retrospective review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of China Medical University approved this study.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent for publication
Patients signed informed consent regarding publishing their data and photographs.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yan, W., Wu, B., Liao, AJ. et al. Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study. Ann Hematol 100, 709–714 (2021). https://doi.org/10.1007/s00277-021-04396-0
- Pulmonary MALT lymphoma